• 182
  • 23
  • 收藏

Novavax says COVID vaccine triggers immune response to Omicron variant

Reuters2021-12-23

Dec 22 (Reuters) - Novavax Inc's COVID-19 vaccine is effective in generating an immune response against the Omicron variant, according to early data published on Wednesday, suggesting that the U.S. drugmaker's existing COVID-19 vaccine can help combat the new Omicron variant.

Novavax's two-dose, protein-based vaccine was authorized for use this week by European Union regulators and the World Health Organization. It has previously been approved by countries including Indonesia and the Philippines but not the United States.

Novavax said that receiving an additional booster dose of Novavax's vaccine further increased people's immune response to Omicron. The data was taken from Novavax's ongoing studies of its vaccine's effectiveness in adolescents and as a booster.

"We are encouraged that boosted responses against all variants were comparable to those associated with high vaccine efficacy in our Phase 3 clinical trials,” said Gregory M. Glenn, Novavax's president of research and development.

Other COVID-19 vaccine manufacturers, including Pfizer Inc. and Moderna Inc., also increase immune responses to Omicron, early data from those companies has shown. Resistance in all cases is stronger in people who have received an additional booster dose.

Novavax is working on developing an Omicron-specific vaccine and said Wednesday it expects to begin manufacturing doses of the variant-specific shot in January.

The drugmaker will start shipping vaccines to the EU's 27 member states in January as part of its deal to supply up to 200 million doses.

The company will also begin shipments in early 2022 to COVAX, a vaccine distribution mechanism overseen by WHO that allocates COVID-19 shots to poorer countries. Novavax and its partner, Serum Institute of India, have agreed to send COVAX more than 1.1 billion doses of Novavax's vaccine.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

举报

评论23

  • Jialatsia
    ·2021-12-23
    Meep
    回复
    举报
  • BigCow
    ·2021-12-23
    K
    回复
    举报
  • 来人
    ·2021-12-23
    Nice
    回复
    举报
  • sk5735
    ·2021-12-23
    Yay
    回复
    举报
    收起
    • CarolTBH
      yes
      2021-12-23
      回复
      举报
  • jokoroksi
    ·2021-12-23
    Yes...4H chart is showing strong reversal. The next should be rally
    回复
    举报
  • ThunkingOne
    ·2021-12-23
    K
    回复
    举报
  • MT8
    ·2021-12-23
    To the Moon...😆
    回复
    举报
    收起
    • sk5735
      😆
      2021-12-23
      回复
      举报
    • ThunkingOne
      k
      2021-12-23
      回复
      举报
  • HumjimPiang8
    ·2021-12-23
    nice
    回复
    举报
  • Zasper
    ·2021-12-23
    Good hor
    回复
    举报
  • 55f64d08
    ·2021-12-23
    K
    回复
    举报
    收起
    • Zasper
      Sian
      2021-12-23
      回复
      举报
    • 55f64d08
      K
      2021-12-23
      回复
      举报
  • 1a327e37
    ·2021-12-23
    K
    回复
    举报
  • dception
    ·2021-12-23
    Woah
    回复
    举报
    收起
  • Koco
    ·2021-12-23
    Yay
    回复
    举报
  • Jess261
    ·2021-12-23
    Okay 
    回复
    举报
  • Aeron2020
    ·2021-12-23
    Ok
    回复
    举报
    收起
    • Koco
      nice
      2021-12-23
      回复
      举报
    • Aeron2020
      [Duh]
      2021-12-23
      回复
      举报
  • Jay88
    ·2021-12-23
    Ok
    回复
    举报
  • bostonxsgp
    ·2021-12-23
    ok
    回复
    举报
    收起
    • Jay88
      ok
      2021-12-23
      回复
      举报
  • kevinlaisq
    ·2021-12-23
    Pls like
    回复
    举报
    收起
  • koolgal
    ·2021-12-23
    Hurray!  Novavax vaccine is on an uptrend on the back of the good news that its vaccine triggers an immune response to Omicron! Go Novavax! 🚀🚀🚀🌙🌙🌙
    回复
    举报
    收起
    • koolgal
      Thanks
      2021-12-23
      回复
      举报
    • koolgal
      Yes!
      2021-12-23
      回复
      举报
    • koolgal
      Thanks
      2021-12-23
      回复
      举报
    查看更多 2 条评论
  • sfleong1
    ·2021-12-23
    Like n comment
    回复
    举报
 
 
 
 

热议股票

 
 
 
 
 

7x24